Government
Houston, TX - BreviTest Technologies has been awarded a $1,500,000 grant from the National Institute on Drug Abuse of the National Institutes of Health to further the commercialization of its point-of-care analyzer for rapid opioid urine testing.
Researchers have developed a precise and non-toxic nanoscale technology that can deliver oncology drugs directly to cancer cells. The minuscule tubes are called peptoids.
Porton Biopharma Ltd has announced that it has signed a modification to its contract with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases to advance a next generation intra-nasal anthrax vaccine into the clinical-trial phase.
Shares of Assertio Therapeutics plunged more than 28% Monday after the company announced the U.S. Food and Drug Administration rejected an injectable formulation of long-acting cosyntropin.
The U.S. Food and Drug Administration approved a new cystic fibrosis medication that is expected to provide treatment for 90% of patients with this debilitating and life-shortening condition.
The decision was based on new analysis run by Biogen in consultation with the FDA of a larger dataset from the trials halted in March.
Comprehensive genomic information of largely understudied Asian populations will expand understanding on the biology of diseases
As an historic lawsuit over opioids was to enter court today, four key defendants reached a settlement.
The approval is based on the Phase III UNIFI study that showed that after eight weeks of taking a single intravenous dose of Stelara, patients saw “clinical remission in a significantly greater proportion of UC patients.”
Thanks to a new regulatory win, AstraZeneca’s Farxiga can now be used to reduce the risk of hospitalization for heart failure in type 2 diabetes patients with cardiovascular disease and with certain risk factors.
PRESS RELEASES